Immunomodulatory Therapy & VSA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-01

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vasospastic angina (VSA) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion. Although vasodilator therapy is widely used and significantly alleviates VSA symptoms, it has not led to notable improvements in the prognosis of patients with VSA. Recent studies have suggested that inflammation plays a crucial role in VSA. This study aimed to evaluate the potential effectiveness of immunomodulatory therapy for improving patient prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris

NCT06415227

Vasospastic Angina

NOT_YET_RECRUITING PHASE2

Treatment of Refractory Angina Pectoris by Shock Wave Therapy

NCT00776568

Angina Pectoris

UNKNOWN PHASE3

The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries

NCT00115583

Atherosclerosis, Coronary

COMPLETED NA

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

NCT00424801

Microvascular Angina Hypertension

TERMINATED NA

Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease

NCT03887013

Coronary Heart Disease Diastolic Dysfunction

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasospastic Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

traditional therapy group

who received nitrate esters, CCBs, anti-platelet agents, and statins

No interventions assigned to this group

immunomodulatory therapy group

who received glucocorticosteroids and/or IVIG in addition to traditional therapy.

glucocorticosteroids and/or intravenous immunoglobulin

Intervention Type DRUG

methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glucocorticosteroids and/or intravenous immunoglobulin

methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(1) Transient total or subtotal occlusion of the coronary artery (contraction \>90%) observed either spontaneously or in response to irritant stimulation (typically acetylcholine, ergot, or hyperventilation); (2) Presence or absence of ischemic electrocardiogram changes during episodes; (3) Nitrate-responsive angina during spontaneous episode: rest angina and/or marked diurnal variation in exercise tolerance and/or episodes precipitated by hyperventilation and/or suppression of episodes by calcium channel blockers.